Version May 2024
| Vesicants |
| Amsacrine |
| Dactinomycin |
| Daunorubicin |
| Doxorubicin |
| Epirubicin |
| Idarubicin |
| Lurbinectedin |
| Mechlorethamine |
| Mitomycin |
| Trabectedin |
| Vinblastine |
| Vincristine and liposomal vincristine |
| Vindesine |
| Vinorelbine |
| Irritants |
| Ado-trastuzumab emtansine* |
| Bendamustine¶ |
| Bleomycin |
| Bortezomib |
| Busulfan |
| Carboplatin |
| Carmustine |
| CisplatinΔ |
| Cladribine |
| Cyclophosphamide |
| Cytarabine |
| DacarbazineΔ |
| Docetaxel |
| Enfortumab vedotin |
| Etoposide |
| Fluorouracil/floxuridine |
| Gemcitabine |
| Ifosfamide |
| Irinotecan¶ |
| Ixabepilone |
| Liposomal daunorubicin¶ |
| Liposomal doxorubicin¶ |
| Melphalan¶ |
| Mitoxantrone¶ |
| Oxaliplatin¶ |
| Paclitaxel¶ |
| Paclitaxel, nanoparticle albumin bound (nabpaclitaxel) |
| Streptozocin |
| Teniposide |
| Topotecan |
* A single case of skin necrosis after ado-trastuzumab emtansine extravasation has been reported.[1]
¶ Irritants that may cause soft tissue injury when extravasated.
Δ May have vesicant properties depending on the concentration of volume of drug extravasated. As an example, extravasation of a large volume (>20 mL) of concentrated cisplatin (>0.5 mg/mL) may produce tissue necrosis.آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟
